AbbVie Inc. $ABBV Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 17.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 219,961 shares of the company’s stock after selling 47,500 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in AbbVie were worth $57,540,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Burk Holdings LLC acquired a new stake in AbbVie during the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC boosted its position in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after buying an additional 48 shares during the period. IMG Wealth Management Inc. grew its stake in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after acquiring an additional 153 shares in the last quarter. Principia Wealth Advisory LLC grew its stake in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after acquiring an additional 44 shares in the last quarter. Finally, Tacita Capital Inc purchased a new stake in shares of AbbVie during the second quarter worth $42,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

AbbVie Stock Performance

Shares of ABBV stock opened at $294.80 on Friday. The stock’s 50-day moving average is $269.35 and its two-hundred day moving average is $237.23. The firm has a market cap of $520.85 billion, a price-to-earnings ratio of 83.28, a PEG ratio of 1.33 and a beta of 0.24. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $298.74.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the prior year, the company earned $1.86 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. As a group, research analysts predict that AbbVie Inc. will post 13.92 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.3%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ABBV. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Leerink Partners increased their price target on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lifted their price objective on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, HSBC boosted their price objective on AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $279.86.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.